GLOBAL HEALTH | GLOBAL PARTNERSHIPS | GLOBAL IMPACT

Research

Photo for PIAAF-Pharmacy

PIAAF-Pharmacy

Official Title

Program for the Identification of “Actionable” Atrial Fibrillation in the Pharmacy Setting: The PIAAF-Pharmacy Study

Status

Ongoing

Overview

To determine the prevalence of “actionable” AF defined as those with (i) previously unrecognized AF and (ii) those with AF but suboptimal anticoagulation therapy through pharmacy-led screening. PIAAF-Pharmacy is a Canadian multicenter study of atrial fibrillation (AF) screening in the community using a novel single-lead ECG device of participants aged 65 and older.

Study Design

Cohort study

Primary Endpoint

The primary outcome will be to determine the prevalence of “actionable” AF in the community through pharmacy- led screening using a handheld ECG device

Number of Patients

2000

Number of Sites

30

Number of Countries

1

Study Period

2014–2015

Principal Investigator

Lisa Dolovich, Roopinder Sandhu, Jeff Healey

Program Manager

Kimberly Begley

Research Coordinator

Alex Grinvalds